In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s shares closed yesterday at $0.48.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Goonewardene covers the Healthcare sector, focusing on stocks such as Exelixis, Merus, and Iovance Biotherapeutics. According to TipRanks, Goonewardene has an average return of -15.3% and a 26.63% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mersana Therapeutics with a $4.67 average price target, implying an 872.92% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $3.00 price target.
Based on Mersana Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $12.6 million and a GAAP net loss of $11.5 million. In comparison, last year the company earned a revenue of $7.7 million and had a GAAP net loss of $41.66 million
Read More on MRSN:
- Positive Outlook for Mersana Therapeutics: Buy Rating Backed by Promising Pipeline and Strong Financial Position
- Mersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges
- Mersana Therapeutics Reports Progress and Financial Results
- Mersana Therapeutics’ Earnings Call Highlights Clinical Progress and Financial Gains
- Mersana Therapeutics: Strong Buy Rating Backed by Robust Financial Performance and Strategic Market Positioning